SGLT-2 Inhibitors, An Issue of Heart Failure Clinics
- 1st Edition, Volume 18-4 - October 11, 2022
- Latest edition
- Editors: Deepak L. Bhatt, Ragavendra R. Baliga
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 9 6 0 4 6 - 5
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 6 0 4 7 - 2
In this issue, guest editors bring their considerable expertise to this important… Read more
Purchase options
In this issue, guest editors bring their considerable expertise to this important topic.
Provides in-depth reviews on the latest updates in the field, providing actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create these timely topic-based reviews.
Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors
Renoprotective Effects of SGLT2 Inhibitors
SGLT2 Inhibitors in Type 2 Diabetes Mellitus
SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: A Paradigm Shift Toward Dual Cardio-Renal Protection
SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction
SGLT2 Inhibitors in Heart Failure: Early Initiation to Achieve Rapid Clinical Benefits
Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events
SGLT2 Inhibitors and Peripheral Vascular Events: A Review of the Literature
Sodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver Disease
SGLT2 Inhibitors and Safety in Older Patients
Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk
Renoprotective Effects of SGLT2 Inhibitors
SGLT2 Inhibitors in Type 2 Diabetes Mellitus
SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: A Paradigm Shift Toward Dual Cardio-Renal Protection
SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction
SGLT2 Inhibitors in Heart Failure: Early Initiation to Achieve Rapid Clinical Benefits
Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events
SGLT2 Inhibitors and Peripheral Vascular Events: A Review of the Literature
Sodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver Disease
SGLT2 Inhibitors and Safety in Older Patients
Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk
- Edition: 1
- Latest edition
- Volume: 18-4
- Published: October 11, 2022
- Language: English
DB
Deepak L. Bhatt
Deepak L. Bhatt, MD, MPH, is Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital Heart and Vascular Center and Professor of Medicine at Harvard Medical School. A leading authority internationally on interventional cardiology in addition
Affiliations and expertise
Director of Mount Sinai Heart, Dr. Valentin Fuster Professor of Cardiovascular Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USARB
Ragavendra R. Baliga
Affiliations and expertise
Inaugural Director, Cardio-Oncology Center of Excellence Professor of Internal Medicine The Ohio State University Wexner Medical Center, USA